Development initiated for a plasma-derived COVID-19 therapy
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to…
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to treat infected, high-risk individuals with COVID-19.